Top-Rated StocksTop-RatedNASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free RVMD Stock Alerts $36.26 -0.17 (-0.47%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$36.17▼$37.8750-Day Range$29.05▼$37.4152-Week Range$15.44▼$38.73Volume1.37 million shsAverage Volume1.28 million shsMarket Capitalization$5.97 billionP/E RatioN/ADividend YieldN/APrice Target$41.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Revolution Medicines alerts: Email Address Revolution Medicines MarketRank™ Stock AnalysisAnalyst RatingBuy3.10 Rating ScoreUpside/Downside13.6% Upside$41.20 Price TargetShort InterestHealthy7.29% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.91Based on 4 Articles This WeekInsider TradingSelling Shares$630,749 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.18) to ($3.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.36 out of 5 starsMedical Sector114th out of 909 stocksBiological Products, Except Diagnostic Industry11th out of 155 stocks 3.6 Analyst's Opinion Consensus RatingRevolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRevolution Medicines has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.29% of the outstanding shares of Revolution Medicines have been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Revolution Medicines has recently decreased by 26.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revolution Medicines is -0.81. Previous Next 3.8 News and Social Media Coverage News SentimentRevolution Medicines has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Revolution Medicines this week, compared to 3 articles on an average week.Search Interest9 people have searched for RVMD on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows7 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $630,749.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Revolution Medicines are expected to decrease in the coming year, from ($3.18) to ($3.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -9.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -9.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now About Revolution Medicines Stock (NASDAQ:RVMD)Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More RVMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVMD Stock News HeadlinesApril 13, 2024 | insidertrades.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells 2,155 Shares of StockMarch 29, 2024 | insidertrades.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells 1,500 Shares of StockApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.April 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - RVMDApril 17, 2024 | msn.comRevolution Medicines (RVMD) Price Target Increased by 5.15% to 41.65April 15, 2024 | investing.comRevolution Medicines executive sells over $619k in company stockApril 14, 2024 | investing.comRevolution Medicines director sells shares worth $79,735April 14, 2024 | americanbankingnews.comSushil Patel Sells 2,155 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) StockApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.April 14, 2024 | americanbankingnews.comMark A. Goldsmith Sells 7,500 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) StockApril 14, 2024 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $45.00 at OppenheimerApril 12, 2024 | markets.businessinsider.comBuy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer TherapiesApril 11, 2024 | uk.investing.comRevolution Medicines reports progress in RAS cancer therapyApril 10, 2024 | msn.comWhat's Going On With Revolution Medicines Stock?April 10, 2024 | uk.investing.comRevolution Medicines reports breakthrough in RAS-mutant cancer treatmentApril 9, 2024 | globenewswire.comRevolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsApril 8, 2024 | markets.businessinsider.comRevolution Medicines’ Robust Cancer Drug Pipeline Justifies Buy RatingApril 8, 2024 | globenewswire.comRevolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsApril 4, 2024 | globenewswire.comRevolution Medicines to Participate in Upcoming Investor ConferencesMarch 28, 2024 | globenewswire.comRevolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024March 22, 2024 | investing.comRevolution Medicines executive sells over $67,000 in stockMarch 22, 2024 | investing.comRevolution Medicines general counsel sells $39,542 in stockMarch 16, 2024 | finance.yahoo.comRVMD Apr 2024 36.000 callMarch 16, 2024 | finance.yahoo.comRVMD Apr 2024 33.000 putMarch 15, 2024 | ca.finance.yahoo.comRVMD Sep 2024 21.000 putMarch 15, 2024 | finance.yahoo.comRVMD Mar 2024 33.000 putMarch 15, 2024 | finance.yahoo.comRVMD Mar 2024 36.000 callSee More Headlines Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/23/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:RVMD CUSIPN/A CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees378Year FoundedN/APrice Target and Rating Average Stock Price Target$41.20 High Stock Price Target$48.00 Low Stock Price Target$28.00 Potential Upside/Downside+13.6%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-436,370,000.00 Net MarginsN/A Pretax Margin-3,798.71% Return on Equity-38.39% Return on Assets-33.61% Debt Debt-to-Equity RatioN/A Current Ratio13.06 Quick Ratio13.06 Sales & Book Value Annual Sales$11.58 million Price / Sales515.69 Cash FlowN/A Price / Cash FlowN/A Book Value$11.09 per share Price / Book3.27Miscellaneous Outstanding Shares164,690,000Free Float150,691,000Market Cap$5.97 billion OptionableOptionable Beta1.54 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Mark A. Goldsmith Ph.D. (Age 62)CEO, President & Chairman Comp: $1.05MMr. Jack Anders (Age 47)Chief Financial Officer Comp: $544.8kMs. Margaret A. Horn J.D. (Age 61)Chief Operating Officer Comp: $775.6kDr. Stephen M. Kelsey FRC Path. (Age 63)FRCP, M.D., President of Research & Development Comp: $779kMs. Xiaolin Wang (Age 53)Executive Vice President of Clinical Development Comp: $604.1kDr. Martin D. Burke M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardDr. Michael A. Fischbach Ph.D. (Age 43)Academic Co-Founder & Member of Scientific Advisory Board Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerMs. Jan Smith Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsVaxcyteNASDAQ:PCVXExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOCRISPR TherapeuticsNASDAQ:CRSPKrystal BiotechNASDAQ:KRYSView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 3,218 shares on 4/18/2024Ownership: 0.002%Mark A GoldsmithSold 7,500 sharesTotal: $266,100.00 ($35.48/share)Sushil PatelSold 2,155 sharesTotal: $79,735.00 ($37.00/share)Mass General Brigham IncBought 338,191 shares on 4/4/2024Ownership: 0.205%Jeff CisliniSold 1,500 sharesTotal: $46,485.00 ($30.99/share)View All Insider TransactionsView All Institutional Transactions RVMD Stock Analysis - Frequently Asked Questions Should I buy or sell Revolution Medicines stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVMD shares. View RVMD analyst ratings or view top-rated stocks. What is Revolution Medicines' stock price target for 2024? 10 Wall Street analysts have issued twelve-month price targets for Revolution Medicines' stock. Their RVMD share price targets range from $28.00 to $48.00. On average, they expect the company's share price to reach $41.20 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price. View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts. How have RVMD shares performed in 2024? Revolution Medicines' stock was trading at $28.68 at the beginning of the year. Since then, RVMD shares have increased by 26.4% and is now trading at $36.26. View the best growth stocks for 2024 here. Are investors shorting Revolution Medicines? Revolution Medicines saw a decline in short interest in March. As of March 31st, there was short interest totaling 12,000,000 shares, a decline of 26.8% from the March 15th total of 16,400,000 shares. Based on an average daily trading volume, of 1,350,000 shares, the days-to-cover ratio is currently 8.9 days. View Revolution Medicines' Short Interest. When is Revolution Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our RVMD earnings forecast. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) released its quarterly earnings results on Monday, February, 26th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by $0.29. The business earned $0.74 million during the quarter, compared to the consensus estimate of $1.20 million. The firm's revenue for the quarter was down 95.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.63) EPS. What ETFs hold Revolution Medicines' stock? ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Tema Oncology ETF (CANC), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL). When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' stock is owned by many different institutional and retail investors. Top institutional investors include Mass General Brigham Inc (0.21%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Sushil Patel, Thilo Schroeder and Xiaolin Wang. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVMD) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
